|
KMID : 0378019850280070117
|
|
New Medical Journal
1985 Volume.28 No. 7 p.117 ~ p.121
|
|
|
Clebopride Therapy in Patients with Functional Castrointestinal
Disorders
|
|
Ûõý÷ã¯
ÑÑà÷Ö/ÏÓÔÄøõ/ÚÓÎÃâ×/ëÅñ£Ø¹/õËêª/ÑÑÙþæï
|
|
|
Abstract
|
|
|
Twenty-nine patients with functional GI disorders, who werenormal in UGI series or endoscopic examination, and liver function test were treated with Clebopriede (Cleboril?) in a randomized, double-blind fashion. Among them 18 were treated with Clebopride, and 11 with placebo. Patients received either Clebopride (1.5 mg a day) or placebo for a week and symptoms were scored.prestudy and at termination of the study. And the results are as follows:
1. Initial symptoms were pestprandial fullness(86.2%), belching (79. 3%0, flatulence(75.9 %), meteorism(65.5%), anorexia(58.6%), nausea) 58. 6%), asthenia(58.6%), constipation (55..2%), abdominal pain(55.2%), pyrosis(24.1%),. and diarrhea (20.7%). The effect rate (percent of cured and improved cases to total ones) of Clebopride on each symptoms were postprandial fullness (93.3%) belching (92.2%), abdominal pain (90.9%, flatulence (90.9%), meteorism (90.9%), anorexia (87.5%), nausea(80.0%),constipation(70.000), diarrhea (66.6%), asthenia (40.0%), and pyrosis(33.3%).
2. Drowsiness and dry mouth were newly developed in 2 cases seperately.
3. Decrease of symptom score was significantly higher in patients with Clebopride than those with placebo (p<0.01), indicating a significant Clebopride effect when compared to placebo.
In conclusion Clebopride is an effective agent in treating the symptom complex of functional GI disorders.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|